Annuncio pubblicitario
Italia markets close in 4 hours 51 minutes

  • FTSE MIB

    33.781,23
    -100,27 (-0,30%)
     

  • Dow Jones

    37.775,38
    +22,07 (+0,06%)
     

  • Nasdaq

    15.601,50
    -81,87 (-0,52%)
     

  • Nikkei 225

    37.068,35
    -1.011,35 (-2,66%)
     

  • Petrolio

    82,29
    -0,44 (-0,53%)
     

  • Bitcoin EUR

    60.627,42
    +2.712,37 (+4,68%)
     

  • CMC Crypto 200

    1.333,34
    +20,71 (+1,60%)
     

  • Oro

    2.396,40
    -1,60 (-0,07%)
     

  • EUR/USD

    1,0660
    +0,0014 (+0,13%)
     

  • S&P 500

    5.011,12
    -11,09 (-0,22%)
     

  • HANG SENG

    16.224,14
    -161,73 (-0,99%)
     

  • Euro Stoxx 50

    4.911,82
    -24,75 (-0,50%)
     

  • EUR/GBP

    0,8564
    +0,0008 (+0,10%)
     

  • EUR/CHF

    0,9681
    -0,0030 (-0,31%)
     

  • EUR/CAD

    1,4671
    +0,0021 (+0,14%)
     

Amicus Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Amicus Therapeutics, Inc.
·1 minuto per la lettura
Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc.

PHILADELPHIA, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference in New York, NY on Wednesday, September 14, 2022 at 12:20 p.m. E.T.

A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn.

ANNUNCIO PUBBLICITARIO

CONTACT:

Investors:
Amicus Therapeutics
Andrew Faughnan
Executive Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G